Cancer Genome Atlas Begins with 3-Year, $100 Million Pilot

The US National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) today launched the Cancer Genome Atlas (TCGA) Pilot Project, a comprehensive effort to accelerate understanding of the molecular basis of cancer.



NCI Deputy Director Dr. Anna Barker said, "TCGA is a revolutionary program which capitalizes on so much of what we've accomplished in the last 30-plus years of biomedical and cancer research. The Human Genome Project produced an amazing product, and we are now positioned to leverage the human genome sequence for TCGA. This is the first attempt to use large-scale gene sequencing for human health - and I am glad that cancer patients and their families will be the beneficiaries. The project will enable a new generation of discovery and empower translational and clinical research across all sectors. Our intent is that all of the data move quickly into the public domain for everyone's use."



The TCGA Pilot Project will develop and test the science and technology needed to systematically identify the genetic changes in cancers. Such an exploration of the genetic origins of cancers would not have been possible a decade ago. But new technologies and genome analysis tools, especially large-scale genome sequencing, have led scientists to a better understanding of how and why genetic changes cause cancer.



For more information, go to http://cancergenome.nih.gov.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap